Mylan adds to women's healthcare portfolio with launch of generic Depo-Proveraź injection
Mylan announced the U.S. launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Proveraź. U.S. sales for MPA were approximately $181 million for the 12 months ending July 31, 2018, according to IQVIA. October 19, 2018